Published in Bioanalysis on May 01, 2013
Site-specific antibody drug conjugates for cancer therapy. MAbs (2014) 1.74
Population pharmacokinetics of trastuzumab emtansine (T-DM1), a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer: clinical implications of the effect of covariates. Cancer Chemother Pharmacol (2014) 0.84
Native mass spectrometry and ion mobility characterization of trastuzumab emtansine, a lysine-linked antibody drug conjugate. Protein Sci (2015) 0.84
Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov (2017) 0.80
Computational Construction of Antibody-Drug Conjugates Using Surface Lysines as the Antibody Conjugation Site and a Non-cleavable Linker. Cancer Inform (2014) 0.75
Marine Antibody-Drug Conjugates: Design Strategies and Research Progress. Mar Drugs (2017) 0.75
A Phase I Pharmacokinetic Study of Trastuzumab Emtansine (T-DM1) in Patients with Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function. Clin Pharmacokinet (2016) 0.75
Population pharmacokinetics and exposure-response of trastuzumab emtansine in advanced breast cancer previously treated with ≥2 HER2-targeted regimens. Br J Clin Pharmacol (2017) 0.75
Therapist-delivered Internet psychotherapy for depression in primary care: a randomised controlled trial. Lancet (2009) 3.90
Two self-management interventions to improve hypertension control: a randomized trial. Ann Intern Med (2009) 3.13
Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J Clin Oncol (2010) 3.06
Cost effectiveness of ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol (2009) 2.58
Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates. Nat Biotechnol (2012) 2.43
A cell-laden microfluidic hydrogel. Lab Chip (2007) 2.15
Critical roles for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells. Proc Natl Acad Sci U S A (2010) 1.75
A target-mediated model to describe the pharmacokinetics and hemodynamic effects of recombinant human vascular endothelial growth factor in humans. Clin Pharmacol Ther (2002) 1.63
Whole-genome sequencing reveals untapped genetic potential in Africa's indigenous cereal crop sorghum. Nat Commun (2013) 1.60
Increased recipient body mass index is associated with acute rejection and other adverse outcomes after kidney transplantation. Transplantation (2014) 1.57
Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer. Cancer Chemother Pharmacol (2012) 1.57
Henoch-Schönlein purpura with hypocomplementemia. Pediatr Nephrol (2012) 1.54
Autologous fat transfer for facial recontouring: is there science behind the art? Plast Reconstr Surg (2007) 1.54
An evaluation of rapid point-of-collection oral fluid drug-testing devices. J Anal Toxicol (2003) 1.51
Impact of drug conjugation on pharmacokinetics and tissue distribution of anti-STEAP1 antibody-drug conjugates in rats. Bioconjug Chem (2011) 1.40
Reduced dose and intermittent treatment with lapatinib and trastuzumab for potent blockade of the HER pathway in HER2/neu-overexpressing breast tumor xenografts. Clin Cancer Res (2010) 1.39
The immunogenicity of the tumor-associated antigen Lewis(y) may be suppressed by a bifunctional cross-linker required for coupling to a carrier protein. Chemistry (2004) 1.35
Primary-care patients' expectations and experiences of online cognitive behavioural therapy for depression: a qualitative study. Health Expect (2009) 1.33
Dual mTORC2/mTORC1 targeting results in potent suppressive effects on acute myeloid leukemia (AML) progenitors. Clin Cancer Res (2011) 1.29
Dialkylphosphates (DAPs) in fruits and vegetables may confound biomonitoring in organophosphorus insecticide exposure and risk assessment. J Agric Food Chem (2008) 1.29
Extraction of BoNT/A, /B, /E, and /F with a single, high affinity monoclonal antibody for detection of botulinum neurotoxin by Endopep-MS. PLoS One (2010) 1.28
Novel avian-origin human influenza A(H7N9) can be transmitted between ferrets via respiratory droplets. J Infect Dis (2013) 1.28
AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia. Blood (2013) 1.26
Autologous fat transfer national consensus survey: trends in techniques for harvest, preparation, and application, and perception of short- and long-term results. Plast Reconstr Surg (2007) 1.25
An infant-associated bacterial commensal utilizes breast milk sialyloligosaccharides. J Biol Chem (2011) 1.25
Integrating oral and general health screening at senior centers for minority elders. Am J Public Health (2013) 1.24
Taking ecological function seriously: soil microbial communities can obviate allelopathic effects of released metabolites. PLoS One (2009) 1.22
Chemokine-glycosaminoglycan binding: specificity for CCR2 ligand binding to highly sulfated oligosaccharides using FTICR mass spectrometry. J Biol Chem (2005) 1.21
Interferon-dependent engagement of eukaryotic initiation factor 4B via S6 kinase (S6K)- and ribosomal protein S6K-mediated signals. Mol Cell Biol (2009) 1.21
Type I interferon (IFN)-dependent activation of Mnk1 and its role in the generation of growth inhibitory responses. Proc Natl Acad Sci U S A (2009) 1.17
Remodeling bacterial polysaccharides by metabolic pathway engineering. Proc Natl Acad Sci U S A (2009) 1.17
Age-dependent methamphetamine-induced alterations in vesicular monoamine transporter-2 function: implications for neurotoxicity. J Pharmacol Exp Ther (2005) 1.13
Discovery of a novel enzymatic cleavage site for botulinum neurotoxin F5. FEBS Lett (2011) 1.13
Quantitative in situ assay of salicylic acid in tobacco leaves using a genetically modified biosensor strain of Acinetobacter sp. ADP1. Plant J (2006) 1.12
Catabolic fate and pharmacokinetic characterization of trastuzumab emtansine (T-DM1): an emphasis on preclinical and clinical catabolism. Curr Drug Metab (2012) 1.12
2012 white paper on recent issues in bioanalysis and alignment of multiple guidelines. Bioanalysis (2012) 1.09
Clinical implications of pathophysiological and demographic covariates on the population pharmacokinetics of trastuzumab emtansine, a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer. J Clin Pharmacol (2011) 1.08
1-amino-4-benzylphthalazines as orally bioavailable smoothened antagonists with antitumor activity. J Med Chem (2009) 1.08
Comparative genomics of parasitic silkworm microsporidia reveal an association between genome expansion and host adaptation. BMC Genomics (2013) 1.07
Economic evaluation of home blood pressure monitoring with or without telephonic behavioral self-management in patients with hypertension. Am J Hypertens (2009) 1.07
A sialyltransferase mutant with decreased donor hydrolysis and reduced sialidase activities for directly sialylating LewisX. ACS Chem Biol (2012) 1.06
Characterization of intact antibody-drug conjugates from plasma/serum in vivo by affinity capture capillary liquid chromatography-mass spectrometry. Anal Biochem (2011) 1.06
Toward the synthesis of artificial proteins: the discovery of an amphiphilic helical peptoid assembly. Chem Biol (2002) 1.05
N-Terminal 112 amino acid residues are not required for the sialyltransferase activity of Photobacterium damsela alpha2,6-sialyltransferase. Biotechnol Lett (2007) 1.04
'PhysioDirect' telephone assessment and advice services for physiotherapy: protocol for a pragmatic randomised controlled trial. BMC Health Serv Res (2009) 1.04
Bioanalytical assay strategies for the development of antibody-drug conjugate biotherapeutics. Bioanalysis (2013) 1.01
Improved detection of botulinum neurotoxin type A in stool by mass spectrometry. Anal Biochem (2011) 1.01
Cost-effectiveness of therapist-delivered online cognitive-behavioural therapy for depression: randomised controlled trial. Br J Psychiatry (2010) 1.00
Do countries or hospitals with longer hospital stays for acute heart failure have lower readmission rates?: Findings from ASCEND-HF. Circ Heart Fail (2013) 1.00
De novo subtype and strain identification of botulinum neurotoxin type B through toxin proteomics. Anal Bioanal Chem (2012) 0.99
Sialidase substrate specificity studies using chemoenzymatically synthesized sialosides containing C5-modified sialic acids. Org Biomol Chem (2009) 0.99
Essential role for Mnk kinases in type II interferon (IFNgamma) signaling and its suppressive effects on normal hematopoiesis. J Biol Chem (2010) 0.99
The mouse and ferret models for studying the novel avian-origin human influenza A (H7N9) virus. Virol J (2013) 0.99
Proteomic analysis of spore wall proteins and identification of two spore wall proteins from Nosema bombycis (Microsporidia). Proteomics (2008) 0.98
Efficient one-pot multienzyme synthesis of UDP-sugars using a promiscuous UDP-sugar pyrophosphorylase from Bifidobacterium longum (BLUSP). Chem Commun (Camb) (2012) 0.98
One-pot three-enzyme synthesis of UDP-GlcNAc derivatives. Chem Commun (Camb) (2011) 0.97
Multifunctionality of Campylobacter jejuni sialyltransferase CstII: characterization of GD3/GT3 oligosaccharide synthase, GD3 oligosaccharide sialidase, and trans-sialidase activities. Glycobiology (2008) 0.97
Mechanisms of mRNA translation of interferon stimulated genes. Cytokine (2010) 0.97
Probe sialidase substrate specificity using chemoenzymatically synthesized sialosides containing C9-modified sialic acid. Chem Commun (Camb) (2012) 0.96
Bioanalysis of antibody-drug conjugates: American Association of Pharmaceutical Scientists Antibody-Drug Conjugate Working Group position paper. Bioanalysis (2013) 0.96
α6β4 integrin, a master regulator of expression of integrins in human keratinocytes. J Biol Chem (2012) 0.95
Economic evaluation of the HF-ACTION (Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training) randomized controlled trial: an exercise training study of patients with chronic heart failure. Circ Cardiovasc Qual Outcomes (2010) 0.95
Three enzymatically active neurotoxins of Clostridium botulinum strain Af84: BoNT/A2, /F4, and /F5. Anal Chem (2014) 0.95
Highly efficient chemoenzymatic synthesis of β1-3-linked galactosides. Chem Commun (Camb) (2010) 0.95
Clinicopathological study of hysterectomies. J Indian Med Assoc (2002) 0.94
Preclinical safety profile of trastuzumab emtansine (T-DM1): mechanism of action of its cytotoxic component retained with improved tolerability. Toxicol Appl Pharmacol (2013) 0.94
An integrated multiple-analyte pharmacokinetic model to characterize trastuzumab emtansine (T-DM1) clearance pathways and to evaluate reduced pharmacokinetic sampling in patients with HER2-positive metastatic breast cancer. Clin Pharmacokinet (2013) 0.93
Beyond the MEK-pocket: can current MEK kinase inhibitors be utilized to synthesize novel type III NCKIs? Does the MEK-pocket exist in kinases other than MEK? Bioorg Med Chem Lett (2008) 0.93
Fluorescent labeling agents change binding profiles of glycan-binding proteins. Mol Biosyst (2011) 0.93
Identification of longitudinally dynamic biomarkers in Alzheimer's disease cerebrospinal fluid by targeted proteomics. Mol Neurodegener (2014) 0.93
The prevalence of subjective symptoms after exposure to arsenic in drinking water in Inner Mongolia, China. J Epidemiol (2003) 0.92
Trans-sialidase activity of Photobacterium damsela alpha2,6-sialyltransferase and its application in the synthesis of sialosides. Glycobiology (2009) 0.91
An evaluation of selected oral fluid point-of-collection drug-testing devices. J Anal Toxicol (2005) 0.91
Drug interaction potential of trastuzumab emtansine (T-DM1) combined with pertuzumab in patients with HER2-positive metastatic breast cancer. Curr Drug Metab (2012) 0.90
Phase I dose-escalation study of onartuzumab as a single agent and in combination with bevacizumab in patients with advanced solid malignancies. Clin Cancer Res (2014) 0.90
Evaluation of the effects of the Aban Aya Youth Project in reducing violence among African American adolescent males using latent class growth mixture modeling techniques. Eval Rev (2005) 0.90
Well water arsenic exposure, arsenic induced skin-lesions and self-reported morbidity in Inner Mongolia. Int J Environ Res Public Health (2009) 0.90
Sprouty proteins are negative regulators of interferon (IFN) signaling and IFN-inducible biological responses. J Biol Chem (2012) 0.90
Intrinsic contact angle of aqueous phases at membranes and vesicles. Phys Rev Lett (2009) 0.88
Increased mortality associated with well-water arsenic exposure in Inner Mongolia, China. Int J Environ Res Public Health (2009) 0.88
Expression and clinical implications of HAb18G/CD147 in hepatocellular carcinoma. Hepatol Res (2014) 0.88
SWP25, a novel protein associated with the Nosema bombycis endospore. J Eukaryot Microbiol (2009) 0.87
EMMPRIN/CD147 expression is associated with disease-free survival of patients with colorectal cancer. Med Oncol (2013) 0.87
Synthetic disialyl hexasaccharides protect neonatal rats from necrotizing enterocolitis. Angew Chem Int Ed Engl (2014) 0.87
Decreasing the sialidase activity of multifunctional Pasteurella multocida α2-3-sialyltransferase 1 (PmST1) by site-directed mutagenesis. Mol Biosyst (2011) 0.87
A single centre experience of the efficacy and safety of dabigatran etexilate used for stroke prevention in atrial fibrillation. J Thromb Thrombolysis (2014) 0.87
Chemical preparation of sialyl Lewis x using an enzymatically synthesized sialoside building block. Carbohydr Res (2008) 0.87
K12/SECTM1, an interferon-γ regulated molecule, synergizes with CD28 to costimulate human T cell proliferation. J Leukoc Biol (2011) 0.87
Cloning and characterization of a viral α2-3-sialyltransferase (vST3Gal-I) for the synthesis of sialyl Lewisx. Glycobiology (2010) 0.87
Growth suppressive cytokines and the AKT/mTOR pathway. Cytokine (2009) 0.87
In-hospital resource use and medical costs in the last year of life by mode of death (from the HF-ACTION randomized controlled trial). Am J Cardiol (2012) 0.87
Different substrate recognition requirements for cleavage of synaptobrevin-2 by Clostridium baratii and Clostridium botulinum type F neurotoxins. Appl Environ Microbiol (2010) 0.87
Whole-genome sequences of DA and F344 rats with different susceptibilities to arthritis, autoimmunity, inflammation and cancer. Genetics (2013) 0.87
Quantification of botulinum neurotoxin serotypes A and B from serum using mass spectrometry. Anal Chem (2011) 0.86